Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iovate intros new Hydroxycut formula

This article was originally published in The Tan Sheet

Executive Summary

Iovate Health Sciences introduces a new formula for its Hydroxycut line, Thermogenic Hydroxycut Advanced. The product's Web site advertises the formula as containing "all-natural antioxidants," and says the product's key ingredient, caffeine anhydrous, helps increase energy and boost metabolism. The firm withdrew 14 products from its Hydroxycut line May 1 after FDA investigated 23 reports of serious liver-related adverse events - including one death - dating to 2002 (1"The Tan Sheet" May 18, 2009). FDA confirmed that "the only ingredient left in from the original formulation is caffeine" and said it "does not have any evidence that caffeine causes liver toxicity." The firm declined to comment

You may also be interested in...



Hydroxycut Recall Eyed As Trigger For Closer Look At Supplement AERs

The dietary supplement industry looks to FDA's Hydroxycut investigation for a sign on whether the agency will analyze adverse event reports more closely following a high-profile product recall

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel